Anaesthetic drugs & techniques
Major Adverse Cardiovascular Events After Hip Fracture Surgery with Remimazolam or Propofol Total Intravenous Anesthesia: A Retrospective Cohort Study Emulating a Target Trial
Authors' conclusion
Among older adults undergoing hip fracture surgery, 30-day in-hospital MACE and mortality did not differ substantially between remimazolam and propofol
Study context
- Population
- Adults aged 65 to 99 years undergoing hip fracture surgery, multicentre Japanese hospital administrative database, September 2020 to September 2024included in the analysis
- Participants
- 14,027 adults
- Exposure
- Remimazolam vs propofol TIVA
- Outcome
- In-hospital major adverse cardiovascular events (MACE)
- Follow-up
- 30 days
Methodological detailstarget trial emulation, multicentre administrative database, propensity score weighting
- Target trial emulation
- Multicentre administrative database
- Propensity score weighting
Main finding
As reported in the abstract
Each group vs propofolRelative risk (95% CI)P value
Remimazolam
1.04(0.80–1.38)
P = 0.76Each group vs propofolRisk difference (95% CI)
Remimazolam
0.12%(−0.64% to 0.90%)
Observational data: associations, not effects.
Secondary outcomes
30-day all-cause in-hospital mortality
- Did not differ materially between groups
- Propensity score weighting
Sensitivity and subgroup analyses (stratified by baseline cardiovascular risk)
- Findings remained consistent
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Major Adverse Cardiovascular Events After Hip Fracture Surgery with Remimazolam or Propofol Total Intravenous Anesthesia: A Retrospective Cohort Study Emulating a Target Trial. Anesth Analg. Published 15 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →